Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05016037 · ClinicalTrials.gov registry record · NA
Predictors of Speech Ability in Down Syndrome
A NA study, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT05016037 is a NA study that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 18 participants.
The verdict
NCT05016037, a NA study, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
Speech is a critical aspect of the human experience and usually develops in a "seemingly automatic process that continues from birth through adolescence and underlies many related abilities" (e.g., language and reading, see National Academy of Medicine Report on Speech and Language Disorders, 2016). Many individuals with Down Syndrome (Trisomy 21, DS) struggle to communicate and participate more fully in human communication and educational learning experiences because their speech is difficult to understand. The purpose of the proposed project was to measure speech-articulation accuracy and speech intelligibility, and their proposed primary predictors at study entry in 16 children with DS age 4;0 to 17;11). A validated treatment, speech recast intervention (see Yoder, Camarata \& Woynaroski, 2016) was used to drive growth in speech intelligibility as a means of evaluating changes in potential sequelae of change. This study included measures of speech-articulation accuracy, and speech-prosody skills as predictors of speech intelligibility growth in DS.
Interventions
- BEHAVIORAL Lexically based speech recast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2022-02-14 |
| Est. Completion | 2025-04-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05016037
The ClinicalTrials.gov registry entry for NCT05016037 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lexically based speech recast is the first listed.
NCT05016037 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05016037 about?
NCT05016037 is a clinical study titled "Predictors of Speech Ability in Down Syndrome". Speech is a critical aspect of the human experience and usually develops in a "seemingly automatic process that continues from birth through adolescence and underlies many related abilities" (e.g., language and reading, see National Academy of Medicine Report on Speech and Language Disorders, 2016)....
What is the current status of trial NCT05016037?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2022-02-14. Estimated completion is 2025-04-30.
What interventions are being tested in trial NCT05016037?
The interventions under investigation include: Lexically based speech recast (BEHAVIORAL).
Who is sponsoring clinical trial NCT05016037?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.